Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Avidity Biosciences Inc (RNA)

Avidity Biosciences Inc (RNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,144,188
  • Shares Outstanding, K 52,127
  • Annual Sales, $ 9,330 K
  • Annual Income, $ -118,010 K
  • 60-Month Beta 1.10
  • Price/Sales 106.31
  • Price/Cash Flow N/A
  • Price/Book 3.06
Trade RNA with:

Options Overview Details

View History
  • Implied Volatility 70.20% ( -24.82%)
  • Historical Volatility 79.65%
  • IV Percentile 10%
  • IV Rank 30.72%
  • IV High 187.38% on 06/14/22
  • IV Low 18.25% on 03/11/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 54
  • Volume Avg (30-Day) 55
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 3,480
  • Open Int (30-Day) 3,490

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.97
  • Number of Estimates 3
  • High Estimate -0.93
  • Low Estimate -1.00
  • Prior Year -0.68
  • Growth Rate Est. (year over year) -42.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.26 +43.84%
on 08/02/22
22.00 -0.23%
on 08/12/22
+4.37 (+24.86%)
since 07/12/22
3-Month
10.89 +101.56%
on 06/16/22
22.00 -0.23%
on 08/12/22
+9.65 (+78.46%)
since 05/12/22
52-Week
10.89 +101.56%
on 06/16/22
29.25 -24.96%
on 11/19/21
+2.10 (+10.58%)
since 08/12/21

Most Recent Stories

More News
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Lags Revenue Estimates

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -24.32% and 4.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

RNA : 21.95 (+15.40%)
ARMP : 4.22 (-0.71%)
Avidity Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 21.95 (+15.40%)
Avidity Biosciences, Inc. (RNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Avidity Biosciences, Inc. (RNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RNA : 21.95 (+15.40%)
VIR : 28.60 (+2.69%)
What Makes Avidity Biosciences, Inc. (RNA) a New Buy Stock

Avidity Biosciences, Inc. (RNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

RNA : 21.95 (+15.40%)
Avidity Biosciences Supports World Facioscapulohumeral Muscular Dystrophy (FSHD) Day and Presents Preclinical Data from FSHD Program

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 21.95 (+15.40%)
Wall Street Analysts Believe Avidity Biosciences, Inc. (RNA) Could Rally 242%: Here's is How to Trade

The mean of analysts' price targets for Avidity Biosciences, Inc. (RNA) points to a 241.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

RNA : 21.95 (+15.40%)
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 24.47% and 19.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

RNA : 21.95 (+15.40%)
ANGN : 1.0300 (unch)
Inhibrx, Inc. (INBX) Reports Q1 Loss, Misses Revenue Estimates

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -29.03% and 7.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

INBX : 24.46 (+3.95%)
RNA : 21.95 (+15.40%)
Novavax (NVAX) Surges 19.3%: Is This an Indication of Further Gains?

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down...

NVAX : 41.47 (+2.80%)
RNA : 21.95 (+15.40%)
Noteworthy Thursday Option Activity: RNA, BZH, NKLA

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Avidity Biosciences Inc , where a total of 6,182 contracts have traded so far, representing...

RNA : 21.95 (+15.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the...

See More

Key Turning Points

3rd Resistance Point 25.62
2nd Resistance Point 23.81
1st Resistance Point 22.88
Last Price 21.95
1st Support Level 20.14
2nd Support Level 18.33
3rd Support Level 17.40

See More

52-Week High 29.25
Fibonacci 61.8% 22.24
Last Price 21.95
Fibonacci 50% 20.07
Fibonacci 38.2% 17.90
52-Week Low 10.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar